Study #2024-0004
A phase 1, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of APR-1051 in patients with advanced solid tumors.
MD Anderson Study Status
Enrolling
Treatment Agent
APR-1051
Description
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor
Study phase:
Phase I
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-908-4145
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.